非达霉素通过抑制血小板衍生生长因子受体β和糖原合成酶激酶-3β减少肠道成纤维细胞胶原表达
本研究结合空间转录组测序与高通量筛选,在狭窄型克罗恩病患者来源的肠道成纤维细胞、血清外泌体、手术切除回肠组织和小鼠模型中,发现非达霉素可抑制PDGFRβ磷酸化与表达、GSK3β磷酸化及胶原表达,从而抑制肠道纤维化。
要点
- 非达霉素抑制CDSE处理的CD-HIFs中胶原和PDGFRB mRNA表达。
- 非达霉素抑制CDSE处理的CD-HIFs中PDGFRβ和GSK3β磷酸化。
- 口服非达霉素抑制SAMP1/YitFc小鼠回肠纤维化及PDGFRB mRNA表达。
核心结论
- 非达霉素通过降低肠道成纤维细胞中PDGFRβ磷酸化与表达、GSK3β磷酸化及胶原表达来抑制肠道纤维化。
研究设计与样本
- 采用10X Genomics Visium空间RNA测序和高通量筛选发现肠道纤维化分子靶点。
- 使用狭窄型克罗恩病患者来源的原代人肠道成纤维细胞(CD-HIFs)、患者来源血清外泌体(CDSE)、新鲜手术切除全层回肠组织和小鼠肠道纤维化模型。
主要发现
- 空间RNA测序发现狭窄型克罗恩病患者纤维化回肠组织中PDGFRB过表达。
- PDGFRB小干扰RNA抑制CDSE处理的CD-HIFs中胶原表达。
- 高通量筛选鉴定出抑制CDSE处理的CD-HIFs中胶原启动子活性的PDGFRB抑制剂。
- 机器学习和分子对接预测PDGFR为非达霉素的靶点;非达霉素抑制CDSE处理的CD-HIFs和狭窄型克罗恩病患者来源回肠组织中胶原及PDGFRB mRNA表达。
- 在SAMP1/YitFc小鼠中,口服非达霉素抑制回肠纤维化及回肠PDGFRB mRNA表达、PDGFRβ和GSK3β磷酸化,而Pdgfrb和Gsk3b过表达可消除这些效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: About 30%-50% of patients with Crohn's disease (CD) eventually develop intestinal strictures, with intestinal fibrosis being a major component of them. There is currently no approved medication to treat fibrotic strictures. METHODS: 10X Genomics Visium spatial RNA sequencing and high-throughput screening were used to discover the molecular targets of intestinal fibrosis. Stricturing Crohn's disease (CDS) patient-derived primary human intestinal fibroblasts (CD-HIFs), stricturing Crohn's disease patient-derived serum exosomes (CDSE), fresh surgically resected whole-thickness ileal tissues, and mouse models of intestinal fibrosis were used. RESULTS: Spatial RNA sequencing found overexpression of platelet-derived growth factor receptor beta (PDGFRB) in the fibrotic ileal tissues of CDS patients. PDGFRB small interfering RNA inhibited collagen expression in the CDSE-treated CD-HIFs. High-throughput screening identified PDGFRB inhibitors that suppressed collagen promoter activity in CDSE-treated CD-HIFs. A machine learning algorithm and molecular docking predicted PDGFR as a target for fidaxomicin. Fidaxomicin, a Food and Drug Administration-approved drug for Clostridioidesdifficile infection, inhibited collagen and PDGFRB messenger RNA (mRNA) expression in CDSE-treated CD-HIFs and CDS patient-derived ileal tissues. CDSE-treated CD-HIFs had increased PDGFRβ and glycogen synthase kinase-3 alpha/beta (GSK3ɑ/β) phosphorylation. Fidaxomicin inhibited PDGFRβ phosphorylation, PDGFRB mRNA expression, and GSK3β phosphorylation in CDSE-treated CD-HIFs. The antifibrogenic effect of fidaxomicin was attenuated by platelet-derived growth factor-BB (PDGF-BB) and insulin-like growth factor 1, which are a PDGFRβ ligand and a GSK3ɑ/β phosphorylation activator, respectively. In the SAMP1/YitFc mice, oral fidaxomicin treatment inhibited ileal fibrosis and ileal PDGFRB mRNA expression and PDGFRβ and GSK3β phosphorylation, which were abolished by Pdgfrb and Gsk3b overexpression. CONCLUSIONS: Fidaxomicin inhibits intestinal fibrosis by reducing PDGFRβ phosphorylation and expression, GSK3β phosphorylation, and collagen expression in intestinal fibroblasts.
引用
- Irwin S, van Daelen M, Almaraz I, et al. Fidaxomicin Reduces Collagen Expression in Intestinal Fibroblasts Via Platelet-Derived Growth Factor Receptor Beta and Glycogen Synthase Kinase-3 Beta Inhibition. Gastroenterology. 2025. PMID: 40398622. doi:10.1053/j.gastro.2025.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。